Oral Squamous Cell Carcinoma Clinical Trials

Find Oral Squamous Cell Carcinoma Clinical Trials Near You

A Prospective, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab With Cetuximab in Patients With Locally Advanced Resectable Oral Squamous Cell Carcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a single-center, single-arm phase II clinical study designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with cetuximab in patients with locally advanced resectable oral squamous cell carcinoma. The treatment regimen for the experimental group is as follows: The recommended dose of epalorestivolimab is 5 mg/kg. Cetuximab is administered at an initial dose of 400 mg/m² followed by 250 mg/m² once weekly, or alternatively cetuximab 500 mg/m² once every 2 weeks, via intravenous infusion. Each treatment cycle lasts 21 days, with 3 cycles administered preoperatively. Patients will undergo surgical resection at 3 weeks ± 7 days after completion of neoadjuvant therapy, followed by concurrent radiotherapy or chemoradiotherapy at 6 weeks ± 2 weeks postoperatively. One clinical tumor imaging assessment will be performed preoperatively per RECIST v1.1 (Appendix 4). In addition, clinically required assessments including vital signs, physical examination, complete blood count, urinalysis, liver and renal function tests, serum electrolytes, thyroid function, electrocardiogram, ECOG performance status, and quality-of-life questionnaires will be completed on Day 1 of each treatment cycle (refer to the study flowchart for specific assessments at each visit). Subjects with hepatitis virus carriage will have viral load monitoring every 2 to 4 treatment cycles. If PD is assessed per RECIST v1.1 but the subject remains clinically stable or the investigator judges that continued treatment may still benefit the subject, reassessment may be performed 4 weeks later using irRECIST. Treatment may be continued if no progressive disease is identified on reassessment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• \- Aged 18-75 years, male or female;

• Histopathologically confirmed primary stage Ⅲ-Ⅳa surgically resectable oral squamous cell carcinoma, with measurable lesions (≥10 mm on spiral CT, meeting RECIST 1.1 criteria);

• ECOG performance status of 0 or 1;

• Expected survival ≥12 weeks;

• At least one measurable lesion per RECIST 1.1. Previously irradiated lesions may serve as measurable lesions provided disease progression has occurred;

• Availability of tumor tissue for PD-L1 testing (paraffin-embedded specimens obtained within 2 years or fresh tumor tissue);

• Adequate organ function assessed within 14 days prior to the first dose of study drug, defined as:

• Hematology: absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelets (PLT) ≥100×10⁹/L, hemoglobin (HB) ≥9 g/dL (no blood transfusion or component transfusion within 14 days before testing);

• Hepatic: serum total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (AST and ALT ≤5 × ULN permitted in the presence of liver metastases);

• Renal: serum creatinine \<1.5 × ULN, or creatinine clearance ≥60 mL/min; blood urea nitrogen ≤200 mg/L;

• Thyroid-stimulating hormone (TSH) ≤1 × ULN. If TSH is abnormal, free triiodothyronine (FT3) and free thyroxine (FT4) shall be evaluated; subjects with normal FT3 and FT4 may be enrolled;

• Urine protein ≤1+. If urine protein \>1+, 24-hour urine protein quantification is required, with total urinary protein ≤1 g;

• Normal cardiac function: normal electrocardiogram (ECG) or ECG abnormalities of no clinical significance; left ventricular ejection fraction (LVEF) \>50% on echocardiography.

• Female subjects of reproductive potential must have a negative serum pregnancy test before the first dose of study drug;

• Male or female subjects of reproductive potential must use highly effective contraceptive methods throughout the study (e.g., oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicide), and continue contraception for 90 days after treatment completion;

• Subjects voluntarily participate in the study, sign the informed consent form, demonstrate good compliance, and agree to follow-up.

Locations
Other Locations
China
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Guoxin Ren, M.D.
renguoxincn@sina.com
13916948812
Time Frame
Start Date: 2026-10-16
Estimated Completion Date: 2029-10-16
Participants
Target number of participants: 26
Treatments
Experimental: Neoadjuvant treatment arm
iparomlimab and tuvonralimab is 5 mg/kg. Cetuximab is administered at an initial dose of 400 mg/m² followed by 250 mg/m² once weekly, or alternatively cetuximab 500 mg/m² once every 2 weeks, via intravenous infusion. Each treatment cycle lasts 21 days, with 3 cycles administered preoperatively. Patients will undergo surgical resection at 3 weeks ± 7 days after completion of neoadjuvant therapy, followed by concurrent radiotherapy or chemoradiotherapy at 6 weeks ± 2 weeks postoperatively.
Related Therapeutic Areas
Sponsors
Leads: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

This content was sourced from clinicaltrials.gov